Edesa Biotech, Inc. · NASDAQ:EDSA
Edesa Biotech — Investor Presentation (May 2026)
10 slides from Edesa Biotech's investor presentation, May 15, 2026
Slide 1: Introduction to Paridiprubart
Introduction to Paridiprubart An anti-TLR4 mAb for ARDS
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "
Slide 3: Paridiprubart Development Program
Paridiprubart Development Program A Multiple-Threat Medical Countermeasure Host Directed and Threat Agnostic Approach • Paridiprubart (“pari”) is a first-in-class humanized mAb • Interferes with TLR4 dimerization in a ligand-independent manner • Helps alleviate the dysregulated innate immune respons
Slide 4: TLR4 Activation and Critical Illnesses
TLR4 Activation and Critical Illnesses Multiple insults can lead to ARDS through TLR4 activation—Most critically ill patients are managed similarly Inducing Agent/Insult Bacterial (e.g. gram-negative) Host • Acute Respiratory Viral Damage Distress Syndrome • Acute Kidney injury Death (e.g. Influenza
Slide 5: Phase 3 Baseline Characteristics
Phase 3 Baseline Characteristics Intent to treat population comprised of 104 patients on IMV ITT Popula tion (IMV with or without ECMO/ Orga n Support) Paridiprubart + SOC (N=56) Placebo + SOC (N=48) Average Age ARDS Severity Clinical Severity 5% (N=5) IMV 36% IMV with 52.2 Moderate Only (N=37) ECMO
Slide 6: Phase 3 Results – Primary Endpoint 28-Day Mortality
Phase 3 Results – Primary Endpoint 28-Day Mortality Paridiprubart Met Primary and Secondary Endpoints with Statistical Significance Mortality at Day 28* Mortality at Day 60* Summary of Phase 3 Results n=104 n=104 P Value <0.001 P Value =0.003 28-Day Mortality Rate: Paridiprubart had a relative reduc
Slide 7: Paridiprubart Treatment Had Significant Impact on Clinical Improvement
Paridiprubart Treatment Had Significant Impact on Clinical Improvement Treatment Nearly Doubled the Chance of Recovery by Day 28 - ITT Estimated Proportion Achieving a 2-pt Reduction in WHO Scale (p<0.05) Secondary Endpoint Proportion of Patients Who Achieved at Least a 40% 2-Point Reduction in the
Slide 8: Phase 3 Study – Additional Analysis
Phase 3 Study – Additional Analysis Survival Benefit Observed in Broader Population, Across Severity Groups and in Subjects with Serious Comorbidities Non-IMV Population 1 Full Treatment Population (n=174) (n=278) 35% 25% 27% 30% Relative Reduction Relative Reduction Estimated Risk of Mortality by D
Slide 9: To Learn More About These Phase 3 Results, Join Us
To Learn More About These Phase 3 Results, Join Us… Poster - Tonight Oral Presentation ATS 2026 International Conference Par Nijhawan, MD, FRCPC, AGAF Ted Steiner, MD, Principal Investigator “A Phase 3, Multicenter, Double-blind, Placebo Vancouver Coastal Health Research Institute Controlled Study o
Slide 10: www.EdesaBiotech.com
www.EdesaBiotech.com